Acrux(OTC) ARUXF

Acrux Limited specializes in the global development and commercialization of generic and topical pharmaceutical products. The company focuses on testosterone therapies and estradiol sprays, catering to both men and women in need of hormone replacement therapies.

Products and Services

• Diverse testosterone therapies in various forms
• Estradiol sprays marketed as Evamist and Lenzetto
• Topical gels and injections for hormone replacement

Growth Outlook

• Recent quarterly revenue reached AUD 1,739,316, showing potential for growth
• Gross profit margin improved to 87.24% in the latest quarter
• Expansion into international markets enhances revenue opportunities

Financial Highlights

• Trailing twelve months (TTM) revenue of AUD 4,409,000
• Net income of AUD 164,934 reported in the latest quarter
• Current ratio of 1.35 indicates solid short-term financial health

Acrux Limited operates in the biotechnology sector, focusing on hormone replacement therapies that address significant health issues. The company's diverse product offerings, including testosterone therapies and estradiol sprays, position it well within the growing healthcare market. Recent financial performance indicates a positive trajectory, with a notable increase in quarterly revenue and an impressive gross profit margin. The current ratio suggests that Acrux is managing its short-term liabilities effectively, which is crucial for sustaining operations and funding future growth initiatives. As the company continues to expand its reach into international markets, it may present attractive opportunities for investors interested in the biotechnology sector.